Floré Clinical and Evexia Diagnostics team up on microbiome mapping tech distribution
05 Jun 2024 --- Gut health testing specialist Floré Clinical has signed a distribution agreement with Evexia Diagnostics to make the personalized microbiome mapping technology GI SereniT available to 20,000 clinical practitioners. Floré provides the proprietary technology, while Evexia represents a substantial network of clinicians.
“About 15% of the population suffers from unresolved gastrointestinal issues. Leveraging advanced microbiome mapping methods, personalized gut health testing technology like GI SereniT helps people get to the root cause of their health problems faster,” says Sunny Jain, founder and chief executive officer of Floré.
“Enabled by Evexia’s vast network of clinicians and laboratory services, we will bring these offerings to more people than ever before and create custom, meaningful solutions that provide lasting effects on patients’ health.”
A standard of care ideal
Floré Clinical specializes in made-to-order probiotics based on an individual’s gut microflora. Evexia Diagnostics is a cutting-edge platform that directly links clinicians with the testing, diagnostic panels and health information they need to help patients.
Together, the companies are expanding access to precision nutrition solutions and advancing the effort to make personalized microbiome testing part of the standard of care in clinical settings.
GI SereniT performs thorough stool analysis via Whole Genome Sequencing of the gut microbiome. The at-home stool test provides patients with clinically relevant insight into gut dysbiosis, microbiome diversity, pathogenic bacteria, irritable bowel syndrome and more.
It identifies over 25,000 organism species while revealing information about gastrointestinal symptoms that many suffer from, such as gas, bloating and stomach pain. Once the results are received, Floré creates a custom probiotic/prebiotic formula customized to the patient’s gut health.
Replacing outdated methods
As clinicians become aware of the testing technology, Floré believes microbiome analysis will become the new standard of care, replacing outdated methods of analysis like culturing, polymerase chain reaction or quantitative polymerase chain reaction.
“Floré Clinical is doing something special. They deliver next-generation testing by equipping providers with interpretation and solutions. As Floré Clinical continues to see success by offering unilateral solutions to healthcare practitioners, we will see a series of companies following their footsteps,” says Ryan Obermeier, vice president and chief commercial officer of Evexia Diagnostics.
Meanwhile, researchers at the University of Massachusetts Lowell’s Zuckerberg College of Health Sciences, US, are exploring the effect of gut microorganisms on the onset of disease, which they believe will facilitate early detection and improved treatments, especially for cognitive disorders such as Alzheimer’s and Parkinson’s.
In addition, the US National Institute of General Medical Science, part of the National Institutes of Health, awarded a US$1.9 million five-year research grant to help understand how complex communities of microbes impact human health.
By Inga de Jong
